Discover trends, market shifts, and competitive outlooks for the ischemic heart disease (ihd) drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Ischemic Heart Disease (IHD) Drugs Market From 2025 To 2029?

The market size for ischemic heart disease (IHD) medications has robustly expanded in recent years. It is projected to increase from $6.36 billion in 2024 to $6.71 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The prior growth can be associated with the escalating worldwide incidence of ischemic heart disease, enhanced consciousness and diagnostic measures, alterations in lifestyle and eating habits, government strategies for heart health, cooperative efforts for clinical studies, and insurance coverage along with reimbursement policies.

Predictions indicate consistent growth in the ischemic heart disease (IHD) drugs market in the upcoming years, expected to reach $7.86 billion in 2029 with a compound annual growth rate (CAGR) of 4.0%. Factors such as the aging population, personalized medicine strategies, emphasis on preventing cardiovascular diseases, worldwide health policies, and global research partnerships contribute to the growth expected during this period. Noteworthy trends for this forecast period involve a transition towards precision medicine, a focus on new anti-atherogenic agents, progress in lipid-lowering treatments, inclusion of anti-inflammatory agents, and the creation of antithrombotic and antiplatelet drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Ischemic Heart Disease (IHD) Drugs Market?

The rise in obesity and diabetes is projected to boost the Ischemic Heart Disease (IHD) drug market’s growth. Diabetes, a long-term metabolic disorder that leads to increased blood glucose levels, and obesity, a condition where excess body fat accumulates, affecting health negatively, often necessitate the use of ischemic heart disease drugs. These drugs are utilized to control cardiovascular risk factors, such as hypertension and dyslipidemia, in individuals with obesity and diabetes, thus minimizing the chance of ischemic heart disease. For example, the World Obesity Federation predicted in 2022 that by 2030, a billion people worldwide—1 in every 5 women and 1 in every 7 men—will have obesity. In another example, the National Health Service reported in June 2024 that in 2023, they identified over half a million (549,000) extra at-risk individuals for developing type 2 diabetes in England. The total number of people registered with non-diabetic hyperglycemia, or pre-diabetes rose to 3,615,330, a significant surge from 3,065,825 in 2022, indicating an increase of nearly 20%. Consequently, the escalating prevalence of obesity and diabetes is contributing to the growth of the IHD drugs market. The surge in heart failure occurrences is expected to push the Ischemic Heart Disease (IHD) drugs market’s growth. Heart failure, a chronic disease where the heart muscle fails to supply enough blood to meet the body’s oxygen and blood needs, can lead to tiredness, difficulties in breathing, and challenges in conducting regular activities. IHD drugs have a crucial role in treating heart failure, mitigating ischemic heart disease risk factors and symptoms, and preventing heart failure altogether. These drugs inhibit the heart’s pacemaker activity and are useful in managing heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For example, according to the Heart Failure Society of America in September 2023, over 6.7 million Americans aged 20 and above have heart failure, a figure expected to increase to 8.5 million Americans by 2030. Hence, the growing incidence of heart failure is accelerating the Ischemic Heart Disease (IHD) drug market’s expansion.

Which Key Market Segments Comprise the Ischemic Heart Disease (IHD) Drugs Market and Drive Its Revenue Growth?

The ischemic heart disease (IHD) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13467&type=smp

Which Areas Are Leading Regions in the Ischemic Heart Disease (IHD) Drugs Market Expansion Across the Globe?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theIschemic Heart Disease (IHD) Drugs Market Over the Coming Years?

Leading businesses within the ischemic heart disease (IHD) drugs market are making strides in the development of innovative myosin inhibitors to secure their market position. Cardiac myosin inhibitors are designed to dampen the activity levels of myosin in the heart muscle, thereby reducing the force of contractions and bringing therapeutic benefits in situations like hypertrophic cardiomyopathy (HCM) where excess muscle thickness hampers heart function. Bristol Myers Squibb, a pharmaceutical firm based in the US, took an example of this initiative when they launched Camzyos (mavacamten) in April 2022. This is the debut cardiac myosin inhibitor designed to augment the functional capacity and symptom management for adults diagnosed with symptomatic New York heart association class II-III obstructive hypertrophic cardiomyopathy (HCM). The drug operates as a selective reversible inhibitor for cardiac myosin, effectively curbing hypercontractility, left ventricular hypertrophy, and bettering cardiac filling pressures. This, in effect, minimizes the dynamic left ventricular outflow tract (LVOT) obstruction.

View the full report here:

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

How Is the Ischemic Heart Disease (IHD) Drugs Market Conceptually Defined?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model